Phenobarbital
Aliases: Pheno, Luminal, Solfoton, Phenobarb, Phenobarbitone
Summary
Phenobarbital is a long-acting barbiturate with extremely slow elimination and a narrow therapeutic window. It binds to a distinct allosteric site on GABA-A receptors separate from benzodiazepines, making combinations particularly dangerous as effects potentiate multiplicatively. Tolerance develops rapidly but not to lethal doses, narrowing the safety margin.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 50-100mg | 100-150mg | 150-300mg | 300mg+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 15-60 min | 1-2 hrs | 4-6 hrs | 12-24 hrs |
| Intravenous | 5 min | - | 15-30 min | 12-24 hrs |
Tolerance
Tolerance Decay
Tolerance to sedative effects typically builds with regular daily use over 1–2+ weeks and decays slowly over several weeks; data are largely clinical experience and user reports rather than controlled studies. Cross-tolerance with other positive GABAA modulators (e.g., benzodiazepines) is partial but clinically relevant. Because of phenobarbital’s long half-life, perceived tolerance may reflect accumulation rather than receptor-level changes.
Cross-Tolerances
Effects
Aggregated from 4 Erowid experience reports